Get started
Author

Damir Varešlija

Observed names: D Damir Vareslija, D Vareslija, D Varešlija, D. Vareslija, D. Varešlija, Damir Vareslija, Damir Vareslija (7895321), Vareslija, Damir, Varešlija, Damir
Observed institutions: University College Dublin, University of Iowa, Royal College of Surgeons in Ireland, University of Liverpool, University of Pittsburgh, University of Washington, Trinity College Dublin, University of Medicine and Health Sciences, Beaumont Hospital, Royal Liverpool University Hospital, Walton Centre, Clatterbridge Cancer Centre NHS Foundation Trust, University Medical Center Utrecht, Fred Hutch Cancer Center, OncoMark (Ireland), Foundation Medicine (United States), Charité - Universitätsmedizin Berlin
ORCID: 0000-0003-1000-0357
Observed ORCID: 0000-0003-1000-0357
OpenAlex ID: A5089906606
Highly reactive oxygen species: detection, formation, and possible functions
2011 · Wolfhardt Freinbichler, Maria A. Colivicchi, et al. · Cellular and Molecular Life Sciences · 181
Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases
2016 · Nolan Priedigkeit, Ryan J. Hartmaier, et al. · JAMA Oncology · 166
Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets
2018 · Damir Varešlija, Nolan Priedigkeit, et al. · JNCI Journal of the National Cancer Institute · 124
PDF
Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines
2020 · Manuel Valiente, Amanda E.D. Van Swearingen, et al. · Cancer Research · 122
Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities
2022 · Nicola Cosgrove, Damir Varešlija, et al. · Nature Communications · 91
PDF
Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism
2022 · Cátia Monteiro, Lauritz Miarka, et al. · Nature Medicine · 85
PDF
6-Hydroxydopamine: a far from simple neurotoxin
2020 · Damir Varešlija, Keith F. Tipton, et al. · Journal of Neural Transmission · 77
AIB1:ERα Transcriptional Activity Is Selectively Enhanced in Aromatase Inhibitor–Resistant Breast Cancer Cells
2012 · Jane O'Hara, Damir Vareslija, et al. · Clinical Cancer Research · 41
Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer
2018 · Alacoque L. Browne, Sara Charmsaz, et al. · Oncogene · 40
PDF
A clinically compatible drug‐screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis
2022 · Lucía Zhu, Diana Retana, et al. · EMBO Molecular Medicine · 38
PDF
FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues
2020 · Alba Font-Tello, Nikolas Kesten, et al. · Nature Protocols · 36
Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy
2015 · Jean McBryan, Ailís Fagan, et al. · Clinical Cancer Research · 35
PARP Inhibitors in Breast Cancer: a Short Communication
2024 · Gordon R. Daly, Maen Monketh AlRawashdeh, et al. · Current Oncology Reports · 31
PDF
Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors
2016 · Damir Varešlija, Jean McBryan, et al. · Clinical Cancer Research · 31
PDF
A novel panel of differentially-expressed microRNAs in breast cancer brain metastasis may predict patient survival
2019 · Athina Giannoudis, Kim Clarke, et al. · Scientific Reports · 29
PDF
Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype
2021 · Damir Varešlija, Elspeth Ward, et al. · Oncogene · 28
PDF
Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity
2023 · Stefan Prekovic, Theofilos Chalkiadakis, et al. · EMBO Molecular Medicine · 25
PDF
Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression
2022 · A. Giannoudis, D. Varešlija, et al. · ESMO Open · 25
PDF
Epigenome-wide SRC-1–Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast Cancer
2018 · Elspeth Ward, Damir Varešlija, et al. · Clinical Cancer Research · 24
The epigenetic landscape of brain metastasis
2025 · Aoibhín M. Powell, Louise Watson, et al. · Oncogene · 23
BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
2019 · Louise Walsh, Kathryn E. Haley, et al. · Clinical Cancer Research · 19
PDF
Low cleaved caspase-7 levels indicate unfavourable outcome across all breast cancers
2018 · Andreas U. Lindner, Federico Lucantoni, et al. · Journal of Molecular Medicine · 19
Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape
2024 · Gordon R. Daly, Sindhuja Naidoo, et al. · Current Oncology Reports · 18
PARP Inhibitors in the Neoadjuvant Setting; A Comprehensive Overview of the Rationale for their Use, Past and Ongoing Clinical Trials
2025 · Minatoullah Habaka, Gordon R. Daly, et al. · Current Oncology Reports · 17
PDF
ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis
2020 · Sara Charmsaz, Ben Doherty, et al. · BMC Medicine · 17
PDF
Works count: 220
Citation count: 1,453
H-index: 20
I10-index: 29
Year
Topic
Type